Metabolomics in various Diseases

Metabolomics is a novel approach that potentials to enable the detection of states of disease, to categories the patients based on biochemical profiles and to monitor disease progression. Metabolomic analysis may also be able to orient the choice of therapy, identify responders and predict toxicity, paving the way to a customized therapy.

  • Metabolomics in Neuropsychiatric DisordersMetabolomics approach has revealed new opportunities in diagnostics of devastating disorders like neuropsychiatric disorders. Metabolomics-based technologies have the prospective to map early biochemical fluctuations in disease and hence provide a prospect to develop predictive biomarkers that can be used as indicators of pathological deviations prior to development of clinical symptoms of neuropsychiatric disorders.
  • Metabolomics in Metabolic DisordersMetabolomics uses in the identification of metabolites not previously associated with metabolic traits highlight the importance and agitations of particular metabolites and advances novel strategies to prevent type 2 diabetes and illustrate biomarkers that can help with early detection, disease progression and therapeutic response. Consequently, the use of metabolomics in this area will continue to grow in basic research science and clinical medical applications.
  • Metabolomics in Cardiovascular DiseasesCardiovascular diseases are the leading causes of death worldwide. There is a need for the development of particular diagnostic techniques, more effective therapeutic procedures as well as drugs, which can decrease the mortality rate in the course of CVDs. Metabolomic technologies may serve as diagnostic and/or prognostic tools that have the potential to significantly alter the management of CVD. Metabolomics can assist in the interpretation of perturbed metabolic processes, and improves our ability to understand the pathology of ischemic heart disease, atherosclerosis, and heart failure.
  • Metabolomic studies in Rheumatoid ArthritisMetabolites from the nucleic acid and oxidative stress pathways are potential biomarkers for rheumatoid arthritis pathology. Metabolite profiles in rheumatoid arthritis plasma are associated to disease activity and treatment response. Metabolomic studies confirm the hypoxic nature of the inflamed synovial joint in rheumatoid arthritis.
  • Metabolomic studies in Systemic Lupus ErythematousLow histidine levels have been identified in the serum of systemic lupus erythematosus (SLE) and RA could explain the increased incidence of cardiovascular disease observed for both rheumatic diseases. Taurine and citrate levels in the SLE urine metabolome have potential utility as biomarkers for SLE nephritis subtype discrimination.
  • studies in Ankylosing SpondylitisMetabolite levels in serum reflect an alteration in the vitamin D3 metabolism in ankylosing spondylitis. Metabolomic studies of patients and controls identified reduced levels of tryptophan in ankylosing spondylitis, probably due to IFN-γ expression in the disease.
  • Metabolomic studies in Psoriatic ArthritisTo date, no studies have directly compared psoriatic arthritis and psoriasis metabolomics profiles. The urine metabolome in psoriatic arthritis is correlated with the changes in disease activity induced by anti-TNF treatment.
  • Metabolomic studies in OsteoarthritisThe prediction model built from the urine metabolite concentrations correlates significantly with the Kellgren–Lawrence radiographic scores of osteoarthritis severity. The valine/histidine and the xleucine(isoleucine and leucine)/histidine ratios are potential biomarkers of the development of knee osteoarthritis.
  • Metabolomic studies in Gouty ArthritisUric acid is not a sufficiently informative biomarker of gouty arthritis and additional markers must be identified. Gouty arthritis also expresses the common core of serum metabolites found in other prevalent arthritis. This common set of metabolites could be useful for the development of improved diagnostic systems.
  • Metabolomics in NephrologyThe application of metabolomics in nephrology research has expanded from the initial analyses of uraemia to include both cross-sectional and longitudinal studies of earlier stages of kidney disease. Chronic kidney disease, Diabetic nephropathy, Acute kidney injury, Kidney transplantation and End-stage renal disease

  • Metabolomics in Neuropsychiatric Disorders
  • Metabolomics in Metabolic Disorders
  • Metabolomics in Cardiovascular Diseases
  • Metabolomic studies in Rheumatoid Arthritis
  • Metabolomic studies in Systemic Lupus Erythematous
  • Metabolomic studies in Ankylosing Spondylitis
  • Metabolomic studies in Psoriatic Arthritis
  • Metabolomic studies in Osteoarthritis
  • Metabolomic studies in Gouty Arthritis
  • Metabolomics in Nephrology

Related Conference of Metabolomics in various Diseases

March 23-24, 2020

World Congress on Biosensors and Bioelectronics

Osaka, Japan
April 16-17, 2020

16th World Congress on Structural Biology

Amsterdam, Netherlands
April 20-21, 2020

11th Tissue Science and Regeneration Congress

Kualalumpur, Malaysia
May 05-06, 2020


Singapore City, Singapore
June 28-30 2020


May 05-06, 2020

Behavioural Science-2020

Rome, Italy
June 28-30 2020

Bioinfo 2020

May 10-11, 2020

26th World Nursing & Nurse Practitioner Conference

Yokohama, Japan
July 17-18, 2020

10th Glycobiology World Congress

Vienna, Austria
August 04-05, 2020

12th Euro Biosensors & Bioelectronics Congress

Zurich, Switzerland
September 22-23, 2020

International Conference on Nucleic Acids

Dubai, UAE
September 28-29, 2020

2nd International Conference on Metabolomics, Genomics and Proteomics

Singapore City, Singapore
September 28-29, 2020

19th International Conference on Structural Biology

Barcelona, Spain
October 08-09, 2020

10th European Biosimilars Summit

Milan, Italy
October 14-15, 2020

9th World Congress on Glycobiology & Glycochemistry

Rome, Italy

Metabolomics in various Diseases Conference Speakers

Recommended Sessions

Related Journals

Are you interested in